PubMed:1726578 JSONTXT

{"project":"Glycan-Motif","denotations":[{"id":"T1","span":{"begin":28,"end":31},"obj":"https://glytoucan.org/Structures/Glycans/G01187XC"},{"id":"T2","span":{"begin":196,"end":199},"obj":"https://glytoucan.org/Structures/Glycans/G01187XC"},{"id":"T3","span":{"begin":684,"end":687},"obj":"https://glytoucan.org/Structures/Glycans/G01187XC"},{"id":"T4","span":{"begin":1125,"end":1151},"obj":"https://glytoucan.org/Structures/Glycans/G58896AZ"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T1","span":{"begin":28,"end":31},"obj":"Glycan_Motif"},{"id":"T2","span":{"begin":196,"end":199},"obj":"Glycan_Motif"},{"id":"T3","span":{"begin":684,"end":687},"obj":"Glycan_Motif"},{"id":"T4","span":{"begin":1125,"end":1151},"obj":"Glycan_Motif"}],"attributes":[{"id":"A1","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G01187XC"},{"id":"A2","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G01187XC"},{"id":"A3","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G01187XC"},{"id":"A4","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G58896AZ"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":28,"end":31},"obj":"https://glytoucan.org/Structures/Glycans/G01187XC"},{"id":"T2","span":{"begin":196,"end":199},"obj":"https://glytoucan.org/Structures/Glycans/G01187XC"},{"id":"T3","span":{"begin":684,"end":687},"obj":"https://glytoucan.org/Structures/Glycans/G01187XC"},{"id":"T4","span":{"begin":1125,"end":1151},"obj":"https://glytoucan.org/Structures/Glycans/G58896AZ"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":133},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":134,"end":462},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":463,"end":701},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":702,"end":888},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":889,"end":1415},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":1416,"end":1658},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":133},"obj":"Sentence"},{"id":"T2","span":{"begin":134,"end":462},"obj":"Sentence"},{"id":"T3","span":{"begin":463,"end":701},"obj":"Sentence"},{"id":"T4","span":{"begin":702,"end":888},"obj":"Sentence"},{"id":"T5","span":{"begin":889,"end":1415},"obj":"Sentence"},{"id":"T6","span":{"begin":1416,"end":1658},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":133},"obj":"Sentence"},{"id":"T2","span":{"begin":134,"end":462},"obj":"Sentence"},{"id":"T3","span":{"begin":463,"end":701},"obj":"Sentence"},{"id":"T4","span":{"begin":702,"end":888},"obj":"Sentence"},{"id":"T5","span":{"begin":889,"end":1415},"obj":"Sentence"},{"id":"T6","span":{"begin":1416,"end":1658},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"Glycosmos6-MAT","denotations":[{"id":"T1","span":{"begin":83,"end":88},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T2","span":{"begin":119,"end":124},"obj":"http://purl.obolibrary.org/obo/MAT_0000098"},{"id":"T3","span":{"begin":581,"end":586},"obj":"http://purl.obolibrary.org/obo/MAT_0000098"},{"id":"T4","span":{"begin":603,"end":608},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":441,"end":447},"obj":"HP_0002664"},{"id":"T1","span":{"begin":441,"end":447},"obj":"HP_0002664"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":83,"end":88},"obj":"FMAID:104231"},{"id":"_T2","span":{"begin":83,"end":88},"obj":"FMAID:14543"},{"id":"_T3","span":{"begin":99,"end":104},"obj":"FMAID:169002"},{"id":"_T4","span":{"begin":99,"end":104},"obj":"FMAID:68646"},{"id":"_T5","span":{"begin":119,"end":124},"obj":"FMAID:50801"},{"id":"_T6","span":{"begin":119,"end":124},"obj":"FMAID:146514"},{"id":"_T7","span":{"begin":125,"end":132},"obj":"FMAID:256050"},{"id":"_T8","span":{"begin":153,"end":164},"obj":"FMAID:82792"},{"id":"_T9","span":{"begin":153,"end":164},"obj":"FMAID:196787"},{"id":"_T10","span":{"begin":369,"end":378},"obj":"FMAID:167148"},{"id":"_T11","span":{"begin":369,"end":378},"obj":"FMAID:62852"},{"id":"_T12","span":{"begin":379,"end":390},"obj":"FMAID:63916"},{"id":"_T13","span":{"begin":379,"end":390},"obj":"FMAID:162384"},{"id":"_T14","span":{"begin":391,"end":413},"obj":"FMAID:67856"},{"id":"_T15","span":{"begin":391,"end":413},"obj":"FMAID:165776"},{"id":"_T16","span":{"begin":391,"end":413},"obj":"FMAID:167238"},{"id":"_T17","span":{"begin":391,"end":413},"obj":"FMAID:165233"},{"id":"_T18","span":{"begin":391,"end":413},"obj":"FMAID:67214"},{"id":"_T19","span":{"begin":391,"end":413},"obj":"FMAID:62914"},{"id":"_T20","span":{"begin":391,"end":413},"obj":"FMAID:62915"},{"id":"_T21","span":{"begin":391,"end":413},"obj":"FMAID:167237"},{"id":"_T22","span":{"begin":448,"end":461},"obj":"FMAID:212684"},{"id":"_T23","span":{"begin":448,"end":461},"obj":"FMAID:200942"},{"id":"_T24","span":{"begin":453,"end":461},"obj":"FMAID:146300"},{"id":"_T25","span":{"begin":453,"end":461},"obj":"FMAID:50594"},{"id":"_T26","span":{"begin":581,"end":586},"obj":"FMAID:50801"},{"id":"_T27","span":{"begin":581,"end":586},"obj":"FMAID:146514"},{"id":"_T28","span":{"begin":603,"end":608},"obj":"FMAID:104231"},{"id":"_T29","span":{"begin":603,"end":608},"obj":"FMAID:14543"},{"id":"_T30","span":{"begin":619,"end":624},"obj":"FMAID:68646"},{"id":"_T31","span":{"begin":619,"end":624},"obj":"FMAID:169002"},{"id":"_T32","span":{"begin":814,"end":817},"obj":"FMAID:272430"},{"id":"_T33","span":{"begin":814,"end":817},"obj":"FMAID:272658"},{"id":"_T34","span":{"begin":814,"end":817},"obj":"FMAID:182506"},{"id":"_T35","span":{"begin":1056,"end":1066},"obj":"FMAID:196773"},{"id":"_T36","span":{"begin":1056,"end":1066},"obj":"FMAID:82780"},{"id":"_T37","span":{"begin":1535,"end":1546},"obj":"FMAID:196792"},{"id":"_T38","span":{"begin":1535,"end":1546},"obj":"FMAID:82797"},{"id":"_T39","span":{"begin":1563,"end":1573},"obj":"FMAID:196773"},{"id":"_T40","span":{"begin":1563,"end":1573},"obj":"FMAID:82780"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":56,"end":77},"obj":"http://www.uniprot.org/uniprot/P21217"},{"id":"T2","span":{"begin":516,"end":536},"obj":"http://www.uniprot.org/uniprot/P21217"},{"id":"T3","span":{"begin":220,"end":226},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T4","span":{"begin":251,"end":257},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T5","span":{"begin":263,"end":269},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T6","span":{"begin":1179,"end":1185},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T7","span":{"begin":1194,"end":1200},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T8","span":{"begin":1206,"end":1212},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T9","span":{"begin":1304,"end":1310},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T10","span":{"begin":1320,"end":1326},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T11","span":{"begin":1332,"end":1338},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T12","span":{"begin":1347,"end":1353},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T13","span":{"begin":1359,"end":1365},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T14","span":{"begin":283,"end":307},"obj":"http://www.uniprot.org/uniprot/P06731"},{"id":"T15","span":{"begin":391,"end":413},"obj":"http://www.uniprot.org/uniprot/P16422"},{"id":"T16","span":{"begin":391,"end":413},"obj":"http://www.uniprot.org/uniprot/P43121"},{"id":"T17","span":{"begin":391,"end":413},"obj":"http://www.uniprot.org/uniprot/Q14CZ8"},{"id":"T18","span":{"begin":391,"end":413},"obj":"http://www.uniprot.org/uniprot/Q8N126"},{"id":"T19","span":{"begin":391,"end":413},"obj":"http://www.uniprot.org/uniprot/Q8NFZ8"},{"id":"T20","span":{"begin":391,"end":413},"obj":"http://www.uniprot.org/uniprot/P50895"},{"id":"T21","span":{"begin":391,"end":413},"obj":"http://www.uniprot.org/uniprot/Q8N3J6"},{"id":"T22","span":{"begin":391,"end":415},"obj":"http://www.uniprot.org/uniprot/Q8N2F4"},{"id":"T23","span":{"begin":391,"end":413},"obj":"http://www.uniprot.org/uniprot/Q92823"},{"id":"T24","span":{"begin":391,"end":415},"obj":"http://www.uniprot.org/uniprot/Q59FL7"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":391,"end":415},"obj":"http://www.uniprot.org/uniprot/Q9Z2H8"},{"id":"T2","span":{"begin":814,"end":817},"obj":"http://www.uniprot.org/uniprot/P00920"},{"id":"T3","span":{"begin":1645,"end":1647},"obj":"http://www.uniprot.org/uniprot/Q8VHK8"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":89,"end":98},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/166034"},{"id":"T2","span":{"begin":99,"end":104},"obj":"http://purl.bioontology.org/ontology/STY/T025"},{"id":"T3","span":{"begin":125,"end":132},"obj":"http://purl.bioontology.org/ontology/STY/T024"},{"id":"T4","span":{"begin":220,"end":224},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T5","span":{"begin":220,"end":224},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T6","span":{"begin":251,"end":255},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T7","span":{"begin":251,"end":255},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T8","span":{"begin":263,"end":267},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T9","span":{"begin":263,"end":267},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T10","span":{"begin":558,"end":572},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/522292"},{"id":"T11","span":{"begin":609,"end":618},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/166034"},{"id":"T12","span":{"begin":619,"end":624},"obj":"http://purl.bioontology.org/ontology/STY/T025"},{"id":"T13","span":{"begin":784,"end":792},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/433098"},{"id":"T14","span":{"begin":1179,"end":1183},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T15","span":{"begin":1179,"end":1183},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T16","span":{"begin":1194,"end":1198},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T17","span":{"begin":1194,"end":1198},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T18","span":{"begin":1206,"end":1210},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T19","span":{"begin":1206,"end":1210},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T20","span":{"begin":1304,"end":1308},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T21","span":{"begin":1304,"end":1308},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T22","span":{"begin":1320,"end":1324},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T23","span":{"begin":1320,"end":1324},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T24","span":{"begin":1332,"end":1336},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T25","span":{"begin":1332,"end":1336},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T26","span":{"begin":1347,"end":1351},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T27","span":{"begin":1347,"end":1351},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T28","span":{"begin":1359,"end":1363},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T29","span":{"begin":1359,"end":1363},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T30","span":{"begin":1483,"end":1488},"obj":"http://purl.bioontology.org/ontology/STY/T096"},{"id":"T31","span":{"begin":1526,"end":1531},"obj":"http://purl.bioontology.org/ontology/STY/T096"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":0,"end":12},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T2","span":{"begin":656,"end":668},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T3","span":{"begin":138,"end":144},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T4","span":{"begin":184,"end":190},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T5","span":{"begin":1037,"end":1043},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T6","span":{"begin":1118,"end":1124},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T7","span":{"begin":1243,"end":1249},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T8","span":{"begin":145,"end":152},"obj":"http://purl.obolibrary.org/obo/GO_0036065"},{"id":"T9","span":{"begin":379,"end":404},"obj":"http://purl.obolibrary.org/obo/GO_0071603"},{"id":"T10","span":{"begin":391,"end":404},"obj":"http://purl.obolibrary.org/obo/GO_0007155"},{"id":"T11","span":{"begin":391,"end":413},"obj":"http://purl.obolibrary.org/obo/GO_0060352"},{"id":"T12","span":{"begin":391,"end":413},"obj":"http://purl.obolibrary.org/obo/GO_0007155"},{"id":"T13","span":{"begin":508,"end":536},"obj":"http://purl.obolibrary.org/obo/GO_0046920"},{"id":"T14","span":{"begin":538,"end":542},"obj":"http://purl.obolibrary.org/obo/GO_0008424"},{"id":"T15","span":{"begin":991,"end":995},"obj":"http://purl.obolibrary.org/obo/GO_0008424"},{"id":"T16","span":{"begin":702,"end":731},"obj":"http://purl.obolibrary.org/obo/GO_0008417"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GO-MF","denotations":[{"id":"T1","span":{"begin":343,"end":349},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T2","span":{"begin":358,"end":365},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T3","span":{"begin":358,"end":365},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T4","span":{"begin":358,"end":365},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T5","span":{"begin":358,"end":365},"obj":"http://purl.obolibrary.org/obo/GO_0005488"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":99,"end":104},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T2","span":{"begin":391,"end":395},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T3","span":{"begin":448,"end":452},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T4","span":{"begin":448,"end":461},"obj":"http://purl.obolibrary.org/obo/GO_0009986"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"UBERON-AE","denotations":[{"id":"T1","span":{"begin":83,"end":88},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T2","span":{"begin":603,"end":608},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T3","span":{"begin":119,"end":124},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"T4","span":{"begin":581,"end":586},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"T5","span":{"begin":125,"end":132},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"EDAM-topics","denotations":[{"id":"T1","span":{"begin":300,"end":307},"obj":"http://edamontology.org/topic_2830"},{"id":"T2","span":{"begin":405,"end":413},"obj":"http://edamontology.org/topic_2839"},{"id":"T3","span":{"begin":597,"end":602},"obj":"http://edamontology.org/topic_2815"},{"id":"T4","span":{"begin":911,"end":918},"obj":"http://edamontology.org/topic_3678"},{"id":"T5","span":{"begin":1026,"end":1036},"obj":"http://edamontology.org/topic_0749"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"EDAM-DFO","denotations":[{"id":"T1","span":{"begin":480,"end":488},"obj":"http://edamontology.org/operation_2423"},{"id":"T2","span":{"begin":1103,"end":1105},"obj":"http://edamontology.org/data_0910"},{"id":"T3","span":{"begin":1224,"end":1226},"obj":"http://edamontology.org/data_0910"},{"id":"T4","span":{"begin":1376,"end":1378},"obj":"http://edamontology.org/data_0910"},{"id":"T5","span":{"begin":1626,"end":1634},"obj":"http://edamontology.org/data_2849"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"NGLY1-deficiency","denotations":[{"id":"PD-NGLY1-deficiency-B_T1","span":{"begin":244,"end":250},"obj":"chem:24139"},{"id":"PD-NGLY1-deficiency-B_T2","span":{"begin":1313,"end":1319},"obj":"chem:24139"}],"namespaces":[{"prefix":"hgnc","uri":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:"},{"prefix":"omim","uri":"https://www.omim.org/entry/"},{"prefix":"chem","uri":"https://pubchem.ncbi.nlm.nih.gov/compound/"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GlycoBiology-MAT","denotations":[{"id":"T1","span":{"begin":83,"end":88},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T2","span":{"begin":119,"end":124},"obj":"http://purl.obolibrary.org/obo/MAT_0000098"},{"id":"T3","span":{"begin":581,"end":586},"obj":"http://purl.obolibrary.org/obo/MAT_0000098"},{"id":"T4","span":{"begin":603,"end":608},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G49112ZN\""},{"id":"GlycanIUPAC_T2","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G50059AJ\""},{"id":"GlycanIUPAC_T3","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G76218YK\""},{"id":"GlycanIUPAC_T4","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G50102KR\""},{"id":"GlycanIUPAC_T5","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G10717VS\""},{"id":"GlycanIUPAC_T6","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G60524RK\""},{"id":"GlycanIUPAC_T7","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G84407TT\""},{"id":"GlycanIUPAC_T8","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G64717JT\""},{"id":"GlycanIUPAC_T9","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G45003TT\""},{"id":"GlycanIUPAC_T10","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G73923FP\""},{"id":"GlycanIUPAC_T11","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G78231MB\""},{"id":"GlycanIUPAC_T12","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G80487UG\""},{"id":"GlycanIUPAC_T13","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G29758MI\""},{"id":"GlycanIUPAC_T14","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G02671KD\""},{"id":"GlycanIUPAC_T15","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G57926TZ\""},{"id":"GlycanIUPAC_T16","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G41718FD\""},{"id":"GlycanIUPAC_T17","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G99840FL\""},{"id":"GlycanIUPAC_T18","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G64321UX\""},{"id":"GlycanIUPAC_T19","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G11231EG\""},{"id":"GlycanIUPAC_T20","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G62741TN\""},{"id":"GlycanIUPAC_T21","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G51576ZQ\""},{"id":"GlycanIUPAC_T22","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G66056LD\""},{"id":"GlycanIUPAC_T23","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G02768BF\""},{"id":"GlycanIUPAC_T24","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G26168RO\""},{"id":"GlycanIUPAC_T25","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G42890HL\""},{"id":"GlycanIUPAC_T26","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G17533VU\""},{"id":"GlycanIUPAC_T27","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G34306RG\""},{"id":"GlycanIUPAC_T28","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G88735KU\""},{"id":"GlycanIUPAC_T29","span":{"begin":230,"end":233},"obj":"\"http://rdf.glycoinfo.org/glycan/G82605UA\""},{"id":"GlycanIUPAC_T30","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T31","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T32","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T33","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T34","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T35","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T36","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T37","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T38","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T39","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T40","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T41","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T42","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T43","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T44","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T45","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T46","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T47","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T48","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T49","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T50","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T51","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T52","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T53","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T54","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T55","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T56","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T57","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T58","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T59","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T60","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T61","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T62","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T63","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T64","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T65","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T66","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T67","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T68","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T69","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T70","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T71","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T72","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T73","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T74","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T75","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T76","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T77","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T78","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T79","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T80","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T81","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T82","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T83","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T84","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T85","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T86","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T87","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T88","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T89","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T90","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T91","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T92","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T93","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T94","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T95","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T96","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T97","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T98","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T99","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T100","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T101","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T102","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T103","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T104","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T105","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T106","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T107","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T108","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T109","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T110","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T111","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T112","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T113","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T114","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T115","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T116","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T117","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T118","span":{"begin":244,"end":250},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T119","span":{"begin":1313,"end":1319},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T120","span":{"begin":1159,"end":1162},"obj":"\"http://rdf.glycoinfo.org/glycan/G16401VC\""},{"id":"GlycanIUPAC_T121","span":{"begin":1284,"end":1287},"obj":"\"http://rdf.glycoinfo.org/glycan/G16401VC\""},{"id":"GlycanIUPAC_T122","span":{"begin":1159,"end":1162},"obj":"\"http://rdf.glycoinfo.org/glycan/G84712AY\""},{"id":"GlycanIUPAC_T123","span":{"begin":1284,"end":1287},"obj":"\"http://rdf.glycoinfo.org/glycan/G84712AY\""},{"id":"GlycanIUPAC_T124","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G59743JO\""},{"id":"GlycanIUPAC_T125","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G22515CP\""},{"id":"GlycanIUPAC_T126","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G50260YT\""},{"id":"GlycanIUPAC_T127","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G59271KV\""},{"id":"GlycanIUPAC_T128","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G41080ZB\""},{"id":"GlycanIUPAC_T129","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G28051VF\""},{"id":"GlycanIUPAC_T130","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G44775RL\""},{"id":"GlycanIUPAC_T131","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G05723ZI\""},{"id":"GlycanIUPAC_T132","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G80753ZP\""},{"id":"GlycanIUPAC_T133","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G09675LS\""},{"id":"GlycanIUPAC_T134","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G32374SR\""},{"id":"GlycanIUPAC_T135","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G35562XQ\""},{"id":"GlycanIUPAC_T136","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G79798HI\""},{"id":"GlycanIUPAC_T137","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G60629WC\""},{"id":"GlycanIUPAC_T138","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G28900GG\""},{"id":"GlycanIUPAC_T139","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G80295GO\""},{"id":"GlycanIUPAC_T140","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G78827BW\""},{"id":"GlycanIUPAC_T141","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G04154TF\""},{"id":"GlycanIUPAC_T142","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G52272JK\""},{"id":"GlycanIUPAC_T143","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G04451ID\""},{"id":"GlycanIUPAC_T144","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G93765AC\""},{"id":"GlycanIUPAC_T145","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G37845XB\""},{"id":"GlycanIUPAC_T146","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G91536UT\""},{"id":"GlycanIUPAC_T147","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G39846RD\""},{"id":"GlycanIUPAC_T148","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G16598ZE\""},{"id":"GlycanIUPAC_T149","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G69175UD\""},{"id":"GlycanIUPAC_T150","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G64029GC\""},{"id":"GlycanIUPAC_T151","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G88005IG\""},{"id":"GlycanIUPAC_T152","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G20950LN\""},{"id":"GlycanIUPAC_T153","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G62915MH\""},{"id":"GlycanIUPAC_T154","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G03187PO\""},{"id":"GlycanIUPAC_T155","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G35637EX\""},{"id":"GlycanIUPAC_T156","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G58694JL\""},{"id":"GlycanIUPAC_T157","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G16024FW\""},{"id":"GlycanIUPAC_T158","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G32353KL\""},{"id":"GlycanIUPAC_T159","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G10359XP\""},{"id":"GlycanIUPAC_T160","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G79996IH\""},{"id":"GlycanIUPAC_T161","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G74945HO\""},{"id":"GlycanIUPAC_T162","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G41472DW\""},{"id":"GlycanIUPAC_T163","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G00508LN\""},{"id":"GlycanIUPAC_T164","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G57307OS\""},{"id":"GlycanIUPAC_T165","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G21068RB\""},{"id":"GlycanIUPAC_T166","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G93716IA\""},{"id":"GlycanIUPAC_T167","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G79555YY\""},{"id":"GlycanIUPAC_T168","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G68618KX\""},{"id":"GlycanIUPAC_T169","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G11806XO\""},{"id":"GlycanIUPAC_T170","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G23375NF\""},{"id":"GlycanIUPAC_T171","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G83211PN\""},{"id":"GlycanIUPAC_T172","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G46248XJ\""},{"id":"GlycanIUPAC_T173","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G50990UV\""},{"id":"GlycanIUPAC_T174","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G11748CA\""},{"id":"GlycanIUPAC_T175","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G47705VB\""},{"id":"GlycanIUPAC_T176","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G56513MF\""},{"id":"GlycanIUPAC_T177","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G29595MF\""},{"id":"GlycanIUPAC_T178","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G79937GD\""},{"id":"GlycanIUPAC_T179","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G83526PI\""},{"id":"GlycanIUPAC_T180","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G72397QO\""},{"id":"GlycanIUPAC_T181","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G19751JJ\""},{"id":"GlycanIUPAC_T182","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G30236YV\""},{"id":"GlycanIUPAC_T183","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G52603CJ\""},{"id":"GlycanIUPAC_T184","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G69831UL\""},{"id":"GlycanIUPAC_T185","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G70447JX\""},{"id":"GlycanIUPAC_T186","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G19550WL\""},{"id":"GlycanIUPAC_T187","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G76492IF\""},{"id":"GlycanIUPAC_T188","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G30921DY\""},{"id":"GlycanIUPAC_T189","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G93844OF\""},{"id":"GlycanIUPAC_T190","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G60958XB\""},{"id":"GlycanIUPAC_T191","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G89925BN\""},{"id":"GlycanIUPAC_T192","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G04660BL\""},{"id":"GlycanIUPAC_T193","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G57508FI\""},{"id":"GlycanIUPAC_T194","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G89416JB\""},{"id":"GlycanIUPAC_T195","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G04443UP\""},{"id":"GlycanIUPAC_T196","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G18920XE\""},{"id":"GlycanIUPAC_T197","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G16975IY\""},{"id":"GlycanIUPAC_T198","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G91289IV\""},{"id":"GlycanIUPAC_T199","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G80908PK\""},{"id":"GlycanIUPAC_T200","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G58337HT\""},{"id":"GlycanIUPAC_T201","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G50847CR\""},{"id":"GlycanIUPAC_T202","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G58393QV\""},{"id":"GlycanIUPAC_T203","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G71104BM\""},{"id":"GlycanIUPAC_T204","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G34414DD\""},{"id":"GlycanIUPAC_T205","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G23241IB\""},{"id":"GlycanIUPAC_T206","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G86119OK\""},{"id":"GlycanIUPAC_T207","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G90738SP\""},{"id":"GlycanIUPAC_T208","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G79621UL\""},{"id":"GlycanIUPAC_T209","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G25287AB\""},{"id":"GlycanIUPAC_T210","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G96108DQ\""},{"id":"GlycanIUPAC_T211","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G12678RQ\""},{"id":"GlycanIUPAC_T212","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G81016FY\""},{"id":"GlycanIUPAC_T213","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G60896QE\""},{"id":"GlycanIUPAC_T214","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G28328IY\""},{"id":"GlycanIUPAC_T215","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G98259SQ\""},{"id":"GlycanIUPAC_T216","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G97961JO\""},{"id":"GlycanIUPAC_T217","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G06186NU\""},{"id":"GlycanIUPAC_T218","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G91012QA\""},{"id":"GlycanIUPAC_T219","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G18124QU\""},{"id":"GlycanIUPAC_T220","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G77966MT\""},{"id":"GlycanIUPAC_T221","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G69065ZM\""},{"id":"GlycanIUPAC_T222","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G56543CB\""},{"id":"GlycanIUPAC_T223","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G48702OS\""},{"id":"GlycanIUPAC_T224","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G49548NQ\""},{"id":"GlycanIUPAC_T225","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G42469OA\""},{"id":"GlycanIUPAC_T226","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G62090LW\""},{"id":"GlycanIUPAC_T227","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G94606VT\""},{"id":"GlycanIUPAC_T228","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G96937AI\""},{"id":"GlycanIUPAC_T229","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G51498DQ\""},{"id":"GlycanIUPAC_T230","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G94744IV\""},{"id":"GlycanIUPAC_T231","span":{"begin":1215,"end":1218},"obj":"\"http://rdf.glycoinfo.org/glycan/G82967ZA\""}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GlycoBiology-Motifs","denotations":[{"id":"T1","span":{"begin":28,"end":31},"obj":"http://rdf.glycoinfo.org/glycan/G00051MO"},{"id":"T2","span":{"begin":196,"end":199},"obj":"http://rdf.glycoinfo.org/glycan/G00051MO"},{"id":"T3","span":{"begin":684,"end":687},"obj":"http://rdf.glycoinfo.org/glycan/G00051MO"},{"id":"T4","span":{"begin":153,"end":164},"obj":"http://rdf.glycoinfo.org/glycan/G00055MO"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":125,"end":132},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":119,"end":124},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":581,"end":586},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":83,"end":88},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":603,"end":608},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GlyCosmos15-HP","denotations":[{"id":"T1","span":{"begin":89,"end":98},"obj":"Phenotype"},{"id":"T2","span":{"begin":441,"end":447},"obj":"Phenotype"},{"id":"T3","span":{"begin":609,"end":618},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0030731"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"HP:0002664"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"HP:0030731"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":83,"end":98},"obj":"Disease"},{"id":"T2","span":{"begin":603,"end":618},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0002032"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0002032"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T1","span":{"begin":1277,"end":1281},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G84034JH"},{"id":"A2","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G84034JH"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":597,"end":602},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":626,"end":630},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":965,"end":969},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":1440,"end":1444},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"307630"},{"id":"A3","pred":"db_id","subj":"T3","obj":"307630"},{"id":"A4","pred":"db_id","subj":"T4","obj":"307630"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":83,"end":88},"obj":"Body_part"},{"id":"T2","span":{"begin":109,"end":124},"obj":"Body_part"},{"id":"T3","span":{"begin":369,"end":378},"obj":"Body_part"},{"id":"T4","span":{"begin":379,"end":395},"obj":"Body_part"},{"id":"T5","span":{"begin":581,"end":586},"obj":"Body_part"},{"id":"T7","span":{"begin":603,"end":608},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0006238"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CL_0000738"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CL_0000115"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"A6","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_6110636"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0001155"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"Anatomy-MAT","denotations":[{"id":"T1","span":{"begin":83,"end":88},"obj":"Body_part"},{"id":"T2","span":{"begin":119,"end":124},"obj":"Body_part"},{"id":"T3","span":{"begin":581,"end":586},"obj":"Body_part"},{"id":"T4","span":{"begin":603,"end":608},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A2","pred":"mat_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MAT_0000098"},{"id":"A3","pred":"mat_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MAT_0000098"},{"id":"A4","pred":"mat_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}

{"project":"Glycosmos15-CL","denotations":[{"id":"T1","span":{"begin":369,"end":378},"obj":"Cell"},{"id":"T2","span":{"begin":379,"end":395},"obj":"Cell"},{"id":"T3","span":{"begin":441,"end":452},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0000738"},{"id":"A2","pred":"cl_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CL:0000115"},{"id":"A3","pred":"cl_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CL:0001063"}],"text":"Biosynthesis in vitro of SA-Lex and SA-diLex by alpha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues.\nThe sialyl-fucosyl-lactosamine-epitope present in sialyl (SA)-Lex (NeuAc alpha 2-3Gal beta 1-4 [Fuc alpha 1-3]GlcNAc beta 1-3Gal beta 1-4Glc-Cer), a carcinoembryonic antigen, has been recognized recently as a ligand for the binding of leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) to myeloid and tumour cell surfaces. We have recently detected the presence of an alpha 1-3 fucosyltransferase (FucT-3) activity in both embryonic chicken brain (ECB) and human colon carcinoma cells (Colo-205) which catalyses the biosynthesis in vitro of SA-Lex and SA-diLex. Fucosyltransferase activities from both sources are stimulated in the presence of divalent cations (Mn2+, Mg2+, Ca2+, Co2+ and Fe2+), although absolute metal requirement is not observed. Substrate specificity studies with this partially purified (ECB, 3000-fold; Colo-205, 100-fold) novel FucT-3 indicate the preference for terminally sialyl-substituted glycolipid acceptors, as observed by the lower Km values when sialyl-neolactotetraosyl ceramide, LM1, (Neu-Gc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4 Glc-Cer; Km = 0.048 mM) and sialyl-norhexaosylceramide, NeuGc-nLc6, (Neu-Gc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer; Km = 0.032 mM) were used as substrates. Fucosyltransferase from Colo-205 requires the presence of the acyl group of the ceramide moiety and an acetyl group on glucosamine in the acceptor glycolipid since lyso-LM1 was found to be completely inactive.(ABSTRACT TRUNCATED AT 250 WORDS)"}